William Slayton, MD - Research

Research at a glance

Top areas of exploration

Hematopoietic Stem Cells , 12 publications
Bone Marrow Transplantation , 10 publications
Bone Marrow Cells , 9 publications
Hematopoietic Stem Cell Transplantation , 8 publications

Research activity

86 publications

2,301 citations

Why is this important?

Active clinical trials

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Ne

Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy using鈥�

Investigators: Brian Stover, William Slayton
Status: Accepting Candidates
Ages: N/A - 21 Years
Sexes: All

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mix

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed鈥�

Investigators: Brian Stover, William Slayton
Status: Accepting Candidates
Ages: 1 Year - 25 Years
Sexes: All

Bleomycin, Carboplatin, Etoposide, or Cisplatin in Pediatric and Adult Patients With Germ Cell Tumor

This partially randomized phase III trial studies how well active surveillance, bleomycin, carboplatin, etoposide, or cisplatin work in treating pediatric and adult patients with germ cell tumors. Active surveillance may help doctors to monitor鈥�

Investigators: Brian Stover, William Slayton
Status: Accepting Candidates
Ages: N/A - N/A
Sexes: All

My publications

86 publications

2008

Philadelphia Chromosome Negative (Ph-) Very High Risk (Vhr) Acute Lymphoblastic Leukemia (All) in Children and Adolescents: the Impact of Intensified Chemotherapy On Early Event Free Survival (Efs) in Children'S Oncology Group (Cog) Study Aall0031

Blood

2008

Recombinant self-complementary adeno-associated virus serotype vector-mediated hematopoietic stem cell transduction and lineage-restricted, long-term transgene expression in a murine serial bone marrow transplantation model.

Human gene therapy

鈥�

2008

Stable integration of recombinant adeno-associated virus vector genomes after transduction of murine hematopoietic stem cells.

Human gene therapy

鈥�

2008

Type 2B von Willebrand disease associated with the release of platelet agglutinates from megakaryocytes in the bone marrow.

Journal of pediatric hematology/oncology

鈥�

2007

Sites and kinetics of donor thrombopoiesis following transplantation of whole bone marrow and progenitor subsets.

Experimental hematology

网红黑料